Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 2 | Unknown | PO / MO |
The patient started Vivotif schedule and took first and second capsule without skipping a day; Case reference number US-BN-2025-001189 is a spontaneous case initially received from a consumer via Communication (reference number: USBAV25-1687) on 10-Jul-2025 and concerns a female patient of unspecified age. The patient's medical history and concomitant medication details were not provided. On 09-Jul-2025, the patient took the first dose of Vivotif (batch number: unknown) orally, at an unknown dose, for an unknown indication. On 10-Jul-2025, one day after the patient took the first dose, the patient took the second dose of Vivotif (batch number: unknown) orally, at an unknown dose (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any adverse events due to Vivotif. No further information was provided.; Reporter's Comments: A female patient of unspecified age took the second dose of Vivotif for an unknown indication one day after the patient took the first dose, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse events due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A female patient of unspecified age took the second dose of Vivotif for an unknown indication one day after the patient took the first dose, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse events due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: NONE